Suppr超能文献

比较 RCHA2DS2-VASc 评分与 CHA2DS2-VASc 评分对 ST 段抬高型心肌梗死患者无复流现象的预测。

Comparison of RCHA2DS2-VASc score and CHA2DS2-VASc score prediction of no-reflow phenomenon in patients with ST-segment elevation myocardial infarction.

机构信息

Department of Cardiology, Tokat State Hospital, Tokat, Turkey.

出版信息

Turk Kardiyol Dern Ars. 2020 Oct;48(7):664-672. doi: 10.5543/tkda.2020.90140.

Abstract

OBJECTIVE

No-reflow is a phenomenon that can arise due to factors such as distal embolization, microvascular occlusion, or prolonged myocardial ischemia and damage. It occurs in about 5% to 10% of patients after primary percutaneous coronary intervention. The CHA2DS2-VASc score can be easily calculated in daily practice and the components of this score are similar to common risk factors for no-reflow. Chronic renal disease generates a hypercoagulable state, which is associated with increased risk of no-reflow in cases of ST-segment elevation myocardial infarction (STEMI). A modified CHA2DS2-VASc score has been developed to include patients with renal dysfunction. The aim of this study was to investigate the prognostic significance of this scoring system, the RCHA2DS2-VASc score, in patients with no-reflow.

METHODS

A total of 75 patients with no-reflow and 1138 patients without no-reflow after STEMI were retrospectively enrolled in this study. The CHA2DS2-VASc and RCHA2DS2-VASc scores of the two groups were compared.

RESULTS

The median CHA2DS2-VASc score and the median RCHA2DS2-VASc score were significantly higher in the no-reflow group (p<.001, for both). There was a statistically significant difference between the groups in all of the components of the CHA2DS2-VASc score. An RCHA2DS2-VASc score of ≥2 was a predictor of no-reflow with a sensitivity of 83% and specificity of 62%.

CONCLUSION

The RCHA2DS2-VASc score is a simple, inexpensive, and easily accessible score to predict no-reflow.

摘要

目的

无复流是一种可能由于远端栓塞、微血管闭塞或心肌缺血和损伤时间延长等因素引起的现象。它发生在大约 5%至 10%的直接经皮冠状动脉介入治疗后的患者中。CHA2DS2-VASc 评分可以在日常实践中轻松计算,该评分的组成部分与无复流的常见危险因素相似。慢性肾病会产生一种高凝状态,这与 ST 段抬高型心肌梗死(STEMI)患者的无复流风险增加有关。已经开发出一种改良的 CHA2DS2-VASc 评分来包括肾功能障碍患者。本研究旨在探讨该评分系统,即 RCHA2DS2-VASc 评分,在无复流患者中的预后意义。

方法

本研究回顾性纳入了 75 例无复流患者和 1138 例 STEMI 后无复流患者。比较两组的 CHA2DS2-VASc 和 RCHA2DS2-VASc 评分。

结果

无复流组的 CHA2DS2-VASc 评分中位数和 RCHA2DS2-VASc 评分中位数均显著升高(均 p<.001)。CHA2DS2-VASc 评分的所有组成部分在两组之间均存在统计学差异。RCHA2DS2-VASc 评分≥2 是无复流的预测因子,其敏感性为 83%,特异性为 62%。

结论

RCHA2DS2-VASc 评分是一种简单、廉价且易于获取的评分系统,可预测无复流。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验